346 related articles for article (PubMed ID: 15200157)
41. The syrian hamster embryo (SHE) cell transformation assay: review of the methods and results.
Mauthe RJ; Gibson DP; Bunch RT; Custer L
Toxicol Pathol; 2001; 29 Suppl():138-46. PubMed ID: 11695550
[TBL] [Abstract][Full Text] [Related]
42. Carcinogenicity of bucetin in (C57BL/6 X C3H)F1 mice.
Togei K; Sano N; Maeda T; Shibata M; Otsuka H
J Natl Cancer Inst; 1987 Nov; 79(5):1151-8. PubMed ID: 3479641
[TBL] [Abstract][Full Text] [Related]
43. The utility of the K6/ODC transgenic mouse as an alternative short term dermal model for carcinogenicity testing of pharmaceuticals.
Miller TJ; Honchel R; Espandiari P; Knapton A; Zhang J; Sistare FD; Hanig JP
Regul Toxicol Pharmacol; 2008 Feb; 50(1):87-97. PubMed ID: 18069108
[TBL] [Abstract][Full Text] [Related]
44. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
45. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.
Storer RD; Sistare FD; Reddy MV; DeGeorge JJ
Toxicol Pathol; 2010 Jan; 38(1):51-61. PubMed ID: 19893055
[TBL] [Abstract][Full Text] [Related]
46. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
47. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene.
Yamamoto S; Hayashi Y; Mitsumori K; Nomura T
Lab Anim Sci; 1997 Apr; 47(2):121-6. PubMed ID: 9150488
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles.
Kirkland D; Aardema M; Müller L; Makoto H
Mutat Res; 2006 Sep; 608(1):29-42. PubMed ID: 16769241
[TBL] [Abstract][Full Text] [Related]
49. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice.
Rebel H; Kram N; Westerman A; Banus S; van Kranen HJ; de Gruijl FR
Carcinogenesis; 2005 Dec; 26(12):2123-30. PubMed ID: 16051635
[TBL] [Abstract][Full Text] [Related]
50. Repair characteristics and differentiation propensity of long-term cultures of epidermal keratinocytes derived from normal and NER-deficient mice.
Backendorf C; de Wit J; van Oosten M; Stout GJ; Mitchell JR; Borgstein AM; van der Horst GT; de Gruijl FR; Brouwer J; Mullenders LH; Hoeijmakers JH
DNA Repair (Amst); 2005 Nov; 4(11):1325-36. PubMed ID: 16182615
[TBL] [Abstract][Full Text] [Related]
51. Mutation spectrum in UVB-exposed skin epidermis of Xpa-knockout mice: frequent recovery of triplet mutations.
Ikehata H; Yanase F; Mori T; Nikaido O; Tanaka K; Ono T
Environ Mol Mutagen; 2007 Jan; 48(1):1-13. PubMed ID: 17163503
[TBL] [Abstract][Full Text] [Related]
52. Cell-type-specific consequences of nucleotide excision repair deficiencies: Embryonic stem cells versus fibroblasts.
de Waard H; Sonneveld E; de Wit J; Esveldt-van Lange R; Hoeijmakers JH; Vrieling H; van der Horst GT
DNA Repair (Amst); 2008 Oct; 7(10):1659-69. PubMed ID: 18634906
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity.
Kirkland D; Aardema M; Henderson L; Müller L
Mutat Res; 2005 Jul; 584(1-2):1-256. PubMed ID: 15979392
[TBL] [Abstract][Full Text] [Related]
54. Oxymetholone: III. Evaluation in the p53+/- transgenic mouse model.
Stoll RE; Holden HE; Barthel CH; Blanchard KT
Toxicol Pathol; 1999; 27(5):513-8. PubMed ID: 10528630
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the levels of enzymes involved in drug metabolism between transgenic or gene-knockout and the parental mice.
Ariyoshi N; Imaoka S; Nakayama K; Takahashi Y; Fujita K; Funae Y; Kamataki T
Toxicol Pathol; 2001; 29 Suppl():161-72. PubMed ID: 11695553
[TBL] [Abstract][Full Text] [Related]
56. In vivo Comet assay on isolated kidney cells to distinguish genotoxic carcinogens from epigenetic carcinogens or cytotoxic compounds.
Nesslany F; Zennouche N; Simar-Meintières S; Talahari I; Nkili-Mboui EN; Marzin D
Mutat Res; 2007 Jun; 630(1-2):28-41. PubMed ID: 17507283
[TBL] [Abstract][Full Text] [Related]
57. Identification of potential biomarkers of genotoxicity and carcinogenicity in L5178Y mouse lymphoma cells by cDNA microarray analysis.
Kim JY; Kwon J; Kim JE; Koh WS; Chung MK; Yoon S; Song CW; Lee M
Environ Mol Mutagen; 2005; 45(1):80-9. PubMed ID: 15612046
[TBL] [Abstract][Full Text] [Related]
58. Combined oral benzo[a]pyrene and inhalatory ozone exposure have no effect on lung tumor development in DNA repair-deficient Xpa mice.
Hoogervorst EM; de Vries A; Beems RB; van Oostrom CT; Wester PW; Vos JG; Bruins W; Roodbergen M; Cassee FR; Vijg J; van Schooten FJ; van Steeg H
Carcinogenesis; 2003 Mar; 24(3):613-9. PubMed ID: 12663525
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration--part I.
Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Savina PM; Santostefano MJ
Int J Toxicol; 2005; 24(5):313-25. PubMed ID: 16257851
[TBL] [Abstract][Full Text] [Related]
60. High-mobility group A1 proteins inhibit expression of nucleotide excision repair factor xeroderma pigmentosum group A.
Adair JE; Maloney SC; Dement GA; Wertzler KJ; Smerdon MJ; Reeves R
Cancer Res; 2007 Jul; 67(13):6044-52. PubMed ID: 17616660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
